Biotech Stocks Update: ZBIO, SPRB, CNTX, OVID Ratings
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
Citi, H.C. Wainwright, JonesResearch, and LifeSci Capital share new ratings and price targets on Zenas BioPharma, Spruce Biosciences, Context Therapeutics, and Ovid Therapeutics.
A hidden cancer company, Context, got a top rating. Its ovarian cancer drug, CTIM-76, has key data coming in 2026.